Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 7.29% | 4.64% | 5.99% | -4.49% | -6.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.29% | 4.64% | 5.99% | -4.49% | -6.69% |
| Cost of Revenue | 363.19% | -31.09% | -36.06% | -49.50% | -143.89% |
| Gross Profit | -19.46% | 17.96% | 22.21% | 15.57% | 20.50% |
| SG&A Expenses | 21.70% | 0.84% | 5.07% | -0.95% | -0.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -84.51% | 33.96% | -542.62% | 37.10% | -124.91% |
| Total Operating Expenses | 81.24% | -7.99% | -13.86% | -16.97% | -33.87% |
| Operating Income | -64.28% | 103.45% | 382.75% | 76.31% | 54.92% |
| Income Before Tax | 15.30% | 79.18% | 745.34% | 309.04% | 222.33% |
| Income Tax Expenses | 50.00% | 138.06% | 337.17% | 177.58% | 57.24% |
| Earnings from Continuing Operations | 6.32% | -16.08% | 405.56% | 364.95% | 360.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00% | -100.00% | -- | 50.00% | 0.00% |
| Net Income | 6.55% | -16.22% | 405.00% | 367.10% | 359.65% |
| EBIT | -64.28% | 103.45% | 382.75% | 76.31% | 54.92% |
| EBITDA | -56.14% | 46.78% | 94.96% | 43.04% | 43.96% |
| EPS Basic | 6.55% | -16.27% | 404.69% | 366.72% | 359.34% |
| Normalized Basic EPS | -67.88% | 141.94% | 802.21% | 100.43% | 60.87% |
| EPS Diluted | 5.88% | -16.19% | 408.70% | 365.12% | 358.76% |
| Normalized Diluted EPS | -67.92% | 142.00% | 802.83% | 100.69% | 59.84% |
| Average Basic Shares Outstanding | 0.00% | 0.06% | 0.06% | 0.06% | 0.13% |
| Average Diluted Shares Outstanding | 0.13% | 0.06% | 0.00% | -0.06% | 0.78% |
| Dividend Per Share | 0.00% | -- | 0.00% | -- | 0.00% |
| Payout Ratio | -- | 0.21% | -- | -0.78% | -- |